lutetium dotatate lu-177 (Lutathera) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA
AACT Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Lutetium Lu 177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSRT2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta emission from Lu 177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells. LUTATHERA® (lutetium Lu 177 dotatate) is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.   NCATS

Chemistry

  • SMILES: [177Lu+3].CC(O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN3CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC3)C(=O)N[C@@H](CC4=CC=C(O)C=C4)C(=O)N[C@H](CC5=CNC6=C5C=CC=C6)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O
  • InChIKey: MXDPZUIOZWKRAA-PRDSJKGBSA-K
  • Mol. Mass: 1609.542
  • ALogP: Missing data
  • ChEMBL Molecule:
    lutetium dotatate lu-177  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$37407.1400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(177lu-dotaotyr3)octreotate | 177lu dota-tate | 177lu-dotatate | 177lu-dota-tate | 177lu-octreotate | (177lutetium-dota(o)tyr3)octreotate | dotatate-177lu | lu177 dota-tate | lu-177 dotate | lutate | lutetium dotatate lu-177

Organizations (43)

Research & Development (42)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (1)


 

Neuroendocrine Tumors

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Breast Neoplasms (Phase 2)

Carcinoid Tumor (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Clinical Trial, Phase I (Phase 1)

Drugs, Investigational (Phase 2)

Glioblastoma (Phase 1)

Glioma (Phase 2)

Intestinal Neoplasms (Phase 3)

Lung Neoplasms (Phase 2)

Meningioma (Phase 2)

Mesothelioma (Phase 1)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 1)

Neuroblastoma (Phase 2)

Neuroendocrine Tumors (Phase 2/Phase 3)

Pancreatic Neoplasms (Phase 3)

Paraganglioma (Phase 2)

Pheochromocytoma (Phase 2)

Pituitary Neoplasms (Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 1)

Small Cell Lung Carcinoma (Phase 1)

Thymoma (Phase 1)

Thyroid Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 36
  • # of Trial Organizations: 42

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue